NR1H4 and metabolic dysfunction-associated steatohepatitis: Currently, FXR agonists are tested in clinical trials for treatment of metabolic and gastrointestinal diseases, including type 2 diabetes (T2DM), metabolic syndrome and Non-Alcoholic Steatohepatitis (NASH).